HC Wainwright Expects Reduced Earnings for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities researchers at HC Wainwright dropped their FY2025 EPS estimates for shares of Dyne Therapeutics in a research note issued on Thursday, November 6th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($3.48) for the year, down from their prior estimate of ($3.40). HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2025 earnings at ($0.76) EPS, FY2026 earnings at ($3.17) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at $1.33 EPS.

Several other brokerages also recently weighed in on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Stifel Nicolaus reduced their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Raymond James Financial upgraded shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Royal Bank Of Canada upped their target price on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Chardan Capital decreased their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.53.

Dyne Therapeutics Trading Up 0.8%

Shares of NASDAQ:DYN opened at $18.51 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The stock’s 50-day moving average is $15.75 and its 200-day moving average is $12.84. The company has a market cap of $2.63 billion, a P/E ratio of -4.80 and a beta of 1.16. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $35.68.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. TD Asset Management Inc acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $258,000. China Universal Asset Management Co. Ltd. increased its stake in Dyne Therapeutics by 9.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after acquiring an additional 2,108 shares during the period. GSA Capital Partners LLP raised its position in Dyne Therapeutics by 152.6% in the third quarter. GSA Capital Partners LLP now owns 35,190 shares of the company’s stock worth $445,000 after purchasing an additional 21,259 shares in the last quarter. Vanguard Group Inc. raised its position in Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after purchasing an additional 278,466 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 2,640 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the transaction, the chief executive officer directly owned 199,539 shares of the company’s stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.14% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.